Litcius/Paper detail

METTL3 increases cisplatin chemosensitivity of cervical cancer cells via downregulation of the activity of RAGE

Ruyi Li, Yizuo Song, Xin Chen, Man Chu, Zhiwei Wang, Xueqiong Zhu

2021Molecular Therapy — Oncolytics32 citationsDOIOpen Access PDF

Abstract

. IHC results showed that the receptor for advanced glycation and products (RAGE) had higher expression levels in cervical cancer tissues. RAGE downregulation increased cell sensitivity to cisplatin treatment. Moreover, the combination of FPS-ZM1 with cisplatin was more effective in inhibiting cell viability as compared with FPS-ZM1 or cisplatin only. Additionally, METTL3 reduced RAGE expression in cervical cancer cells. Overexpression of METTL3 downregulated RAGE expression and caused more sensitivity to cisplatin treatment in the SiHa-DDP cell line. METTL3 inhibited cell viability and increased apoptosis as well as enhanced the sensitivity of cisplatin via downregulating RAGE expression in cervical cancer cells.

Topics & Concepts

CisplatinCancer researchCervical cancerCarcinogenesisDownregulation and upregulationMedicineCancer cellViability assayCancerImmunohistochemistryOvarian cancerApoptosisOncologyInternal medicineChemistryChemotherapyGeneBiochemistryRNA modifications and cancerCancer-related gene regulationEpigenetics and DNA Methylation
METTL3 increases cisplatin chemosensitivity of cervical cancer cells via downregulation of the activity of RAGE | Litcius